600216 浙江医药
已收盘 03-24 15:00:00
资讯
新帖
简况
每周股票复盘：浙江医药（600216）股东拟减持不超1%股份
证券之星 · 03-22
每周股票复盘：浙江医药（600216）股东拟减持不超1%股份
浙江医药最新公告：股东国投高科拟减持不超1%股份
证券之星 · 03-16
浙江医药最新公告：股东国投高科拟减持不超1%股份
每周股票复盘：浙江医药（600216）拟投1.57亿参与生物医药基金
证券之星 · 03-15
每周股票复盘：浙江医药（600216）拟投1.57亿参与生物医药基金
浙江医药（600216）披露与私募基金合作投资公告，3月9日股价下跌4.03%
证券之星 · 03-09
浙江医药（600216）披露与私募基金合作投资公告，3月9日股价下跌4.03%
浙江医药最新公告：以1.57亿元自有资金认缴出资成为厦门华犇启航股权投资合伙企业有限合伙人
证券之星 · 03-09
浙江医药最新公告：以1.57亿元自有资金认缴出资成为厦门华犇启航股权投资合伙企业有限合伙人
每周股票复盘：浙江医药（600216）新码生物获6.2亿增资并推进ARX305 II期临床
证券之星 · 03-08
每周股票复盘：浙江医药（600216）新码生物获6.2亿增资并推进ARX305 II期临床
3月6日浙江医药涨7.86%，长信医疗LOF基金重仓该股
证券之星 · 03-06
3月6日浙江医药涨7.86%，长信医疗LOF基金重仓该股
浙江医药（600216）披露ARX305启动II期临床试验公告，3月5日股价上涨0.77%
证券之星 · 03-05
浙江医药（600216）披露ARX305启动II期临床试验公告，3月5日股价上涨0.77%
浙江医药(600216.SH)：ARX305启动II期临床试验
智通财经 · 03-05
浙江医药(600216.SH)：ARX305启动II期临床试验
浙江医药最新公告：子公司新码生物拟实施C轮增资并引入六名战略投资者
证券之星 · 03-03
浙江医药最新公告：子公司新码生物拟实施C轮增资并引入六名战略投资者
每周股票复盘：浙江医药（600216）拟出资2.5亿元参设银发经济基金
证券之星 · 03-01
每周股票复盘：浙江医药（600216）拟出资2.5亿元参设银发经济基金
浙江医药（600216）披露与私募基金合作投资公告，2月24日股价下跌1.81%
证券之星 · 02-24
浙江医药（600216）披露与私募基金合作投资公告，2月24日股价下跌1.81%
浙江医药(600216.SH)拟参投合伙企业 投向银发经济/医药大健康领域
智通财经 · 02-24
浙江医药(600216.SH)拟参投合伙企业 投向银发经济/医药大健康领域
浙江医药：公司已经建立了财务共享体系
证券日报网 · 02-06
浙江医药：公司已经建立了财务共享体系
每周股票复盘：浙江医药（600216）国投高科减持期满未减持
证券之星 · 01-25
每周股票复盘：浙江医药（600216）国投高科减持期满未减持
浙江医药（600216）披露持股5%以上股东减持计划届满暨未减持股份公告，1月22日股价上涨1.7%
证券之星 · 01-22
浙江医药（600216）披露持股5%以上股东减持计划届满暨未减持股份公告，1月22日股价上涨1.7%
每周股票复盘：浙江医药（600216）完成1024.4万股限制性股票授予
证券之星 · 01-11
每周股票复盘：浙江医药（600216）完成1024.4万股限制性股票授予
浙江医药（600216）披露2025年限制性股票激励计划授予结果，1月6日股价上涨0.72%
证券之星 · 01-06
浙江医药（600216）披露2025年限制性股票激励计划授予结果，1月6日股价上涨0.72%
每周股票复盘：浙江医药（600216）完成限制性股票授予
证券之星 · 01-02
每周股票复盘：浙江医药（600216）完成限制性股票授予
浙江医药（600216）发布向2025年限制性股票激励计划激励对象授予限制性股票公告，11月26日股价上涨0.14%
证券之星 · 2025-11-26
浙江医药（600216）发布向2025年限制性股票激励计划激励对象授予限制性股票公告，11月26日股价上涨0.14%
加载更多
公司概况
公司名称：
浙江医药股份有限公司
所属行业：
医药制造业
上市日期：
1999-10-21
主营业务：
浙江医药股份有限公司的主营业务是生命营养品、药品。公司的主要产品是合成维生素E、维生素A、天然维生素E、维生素H(生物素)、维生素D3、辅酶Q10、β-胡萝卜素、斑蝥黄素、叶黄素、番茄红素等维生素和类维生素产品、医药制造类产品及医药商业。报告期内，公司在CPHI2025荣获“LeadingEnterpriseofPharmaInternationalizationAwards”（医药国际化领军企业奖），在HHB健康美丽产业高质量发展大会被评为“健康美丽产业绿色可持续发展先锋企业”。
发行价格：
5.16
{"stockData":{"symbol":"600216","market":"SH","secType":"STK","nameCN":"浙江医药","latestPrice":14.98,"timestamp":1774335600000,"preClose":14.75,"halted":0,"volume":23439860,"delay":0,"changeRate":0.0156,"floatShares":951000000,"shares":961999999,"eps":1.2937,"marketStatus":"已收盘","change":0.23,"latestTime":"03-24 15:00:00","open":14.98,"high":15.09,"low":14.63,"amount":348000000,"amplitude":0.0312,"askPrice":14.98,"askSize":39,"bidPrice":14.97,"bidSize":291,"shortable":0,"etf":0,"ttmEps":1.2937,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774402200000},"marketStatusCode":5,"adr":0,"adjPreClose":14.75,"symbolType":"stock","openAndCloseTimeList":[[1774315800000,1774323000000],[1774328400000,1774335600000]],"highLimit":16.23,"lowLimit":13.28,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":961637750,"isCdr":false,"pbRate":1.3,"roa":"--","peRate":11.579191,"roe":"8.49%","epsLYR":1.21,"committee":-0.432977,"marketValue":14405000000,"turnoverRate":0.0246,"status":0,"floatMarketCap":14252000000},"requestUrl":"/m/hq/s/600216","defaultTab":"news","newsList":[{"id":"2621795092","title":"每周股票复盘：浙江医药（600216）股东拟减持不超1%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2621795092","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621795092?lang=zh_cn&edition=full","pubTime":"2026-03-22 01:24","pubTimestamp":1774113853,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，浙江医药报收于15.2元，较上周的17.76元下跌14.41%。本周，浙江医药3月16日盘中最高价报18.12元。本周关注点公司公告汇总：股东国投高科计划减持不超过公司总股本的1%公司公告汇总浙江医药股东国投高科技投资有限公司持有公司150,127,573股，占总股本的15.61%。国投高科计划于2026年4月8日至2026年7月7日通过集中竞价交易方式减持不超过9,616,377股，即不超过公司总股本的1%。本次减持不会导致公司控制权变更。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600216","BK0191","BK0188","BK0239"],"gpt_icon":0},{"id":"2619545403","title":"浙江医药最新公告：股东国投高科拟减持不超1%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2619545403","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619545403?lang=zh_cn&edition=full","pubTime":"2026-03-16 18:41","pubTimestamp":1773657668,"startTime":"0","endTime":"0","summary":"浙江医药(600216.SH)公告称，持股5%以上股东国投高科技投资有限公司基于自身经营发展需要，计划于2026年4月8日至2026年7月7日，通过集中竞价交易方式减持不超过961.64万股，占公司总股本的不超过1%；减持股份来源为首次公开发行前持有的股份及由此取得的股票股利。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600028481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","600216","BK0188","BK0191"],"gpt_icon":0},{"id":"2619127208","title":"每周股票复盘：浙江医药（600216）拟投1.57亿参与生物医药基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2619127208","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619127208?lang=zh_cn&edition=full","pubTime":"2026-03-15 01:36","pubTimestamp":1773509773,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘，浙江医药报收于17.76元，较上周的18.38元下跌3.37%。本周，浙江医药3月9日盘中最高价报18.58元，股价触及近一年最高点。浙江医药当前最新总市值170.79亿元，在化学制药板块市值排名30/150，在两市A股市值排名1257/5190。本周关注点公司公告汇总：浙江医药拟出资1.57亿元参与生物医药产业基金投资。公司公告汇总浙江医药股份有限公司与厦门华犇当代创业投资管理有限公司等签署合伙协议，共同投资厦门华犇启航股权投资合伙企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031500000243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["160635","600216","BK0188","BK0191","BK0239","BK0028"],"gpt_icon":0},{"id":"2618717624","title":"浙江医药（600216）披露与私募基金合作投资公告，3月9日股价下跌4.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618717624","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618717624?lang=zh_cn&edition=full","pubTime":"2026-03-09 22:13","pubTimestamp":1773065599,"startTime":"0","endTime":"0","summary":"截至2026年3月9日收盘，浙江医药报收于17.64元，较前一交易日下跌4.03%，最新总市值为169.63亿元。该股当日开盘18.35元，最高18.58元，最低17.5元，成交额达8.51亿元，换手率为5.0%。近日，浙江医药股份有限公司与厦门华犇当代创业投资管理有限公司等签署合伙协议，共同投资厦门华犇启航股权投资合伙企业。本次交易不构成关联交易或重大资产重组，无需提交董事会或股东会审议。基金尚需完成备案程序，存在投资收益不确定等风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030900035098.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","600216","BK0188","BK0191"],"gpt_icon":0},{"id":"2618477306","title":"浙江医药最新公告：以1.57亿元自有资金认缴出资成为厦门华犇启航股权投资合伙企业有限合伙人","url":"https://stock-news.laohu8.com/highlight/detail?id=2618477306","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618477306?lang=zh_cn&edition=full","pubTime":"2026-03-09 18:41","pubTimestamp":1773052884,"startTime":"0","endTime":"0","summary":"浙江医药(600216.SH)公告称，公司与厦门华犇当代创业投资管理有限公司等签署合伙协议，投资厦门华犇启航股权投资合伙企业（有限合伙），认缴出资1.57亿元，占合伙企业认缴出资总额的49.06%。该基金主要聚焦生物医药等战略新兴产业领域，投资比例不低于基金规模的60%。本次交易不构成关联交易，亦不构成重大资产重组。合伙企业可能面临投资项目受多种因素影响导致的不确定性风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030900027755.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600216","BK0028","BK0191","BK0239"],"gpt_icon":0},{"id":"2617668981","title":"每周股票复盘：浙江医药（600216）新码生物获6.2亿增资并推进ARX305 II期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2617668981","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617668981?lang=zh_cn&edition=full","pubTime":"2026-03-08 01:22","pubTimestamp":1772904131,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，浙江医药报收于18.38元，较上周的16.29元上涨12.83%。本周，浙江医药3月6日盘中最高价报18.54元，股价触及近一年最高点。公司公告汇总：ARX305启动II期临床试验，累计研发投入达1.0965亿元。本次增资后，浙江医药持股比例由45.9186%降至37.6347%，新码生物仍为控股子公司，纳入合并报表范围。浙江医药子公司新码生物启动注射用重组人源化抗CD70单抗-AS269偶联物针对复发/难治性淋巴瘤的II期临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800000166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0191","600216","BK0188"],"gpt_icon":0},{"id":"2617683866","title":"3月6日浙江医药涨7.86%，长信医疗LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2617683866","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617683866?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:17","pubTimestamp":1772785037,"startTime":"0","endTime":"0","summary":"证券之星消息，3月6日浙江医药涨7.86%创60日新高，收盘报18.38元，换手率6.59%，成交量62.69万手，成交额11.21亿元。重仓浙江医药的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为长信基金的长信医疗LOF。长信医疗LOF目前规模为1.09亿元，最新净值1.313，较上一交易日上涨1.47%，近一年下跌3.68%。该公募基金现任基金经理为袁婕。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600025484.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600216","BK0191","BK0028","163001","BK0239","BK0188"],"gpt_icon":0},{"id":"2617109355","title":"浙江医药（600216）披露ARX305启动II期临床试验公告，3月5日股价上涨0.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617109355","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617109355?lang=zh_cn&edition=full","pubTime":"2026-03-05 17:26","pubTimestamp":1772702800,"startTime":"0","endTime":"0","summary":"截至2026年3月5日收盘，浙江医药报收于17.04元，较前一交易日上涨0.77%，最新总市值为163.86亿元。近日，浙江医药披露《关于ARX305启动II期临床试验的公告》。公告显示，公司子公司新码生物已启动注射用重组人源化抗CD70单抗-AS269偶联物针对复发/难治性淋巴瘤的II期临床试验。ARX305为1类生物制品，属创新生物技术药物，用于治疗CD70表达的晚期肿瘤。公司已于2022年启动I期临床试验，目前处于剂量扩组阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500028221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","600216","BK0191","BK0188"],"gpt_icon":0},{"id":"2617511420","title":"浙江医药(600216.SH)：ARX305启动II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2617511420","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617511420?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:03","pubTimestamp":1772697821,"startTime":"0","endTime":"0","summary":"智通财经APP讯，浙江医药(600216.SH)公告，公司下属子公司浙江新码生物医药股份有限公司(简称“新码生物”)启动注射用重组人源化抗CD70单抗-AS269偶联物(ARX305)针对复发/难治性淋巴瘤的有效性及安全性的单臂、开放II期临床研究。公告显示，注射用重组人源化抗CD70单抗-AS269偶联物(ARX305)是新码生物于2019年10月22日与美国Ambrx公司签署《合作开发和许可协议》合作研发的新一代单克隆抗体偶联药物，用于治疗CD70表达的晚期肿瘤，属于创新生物技术药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410421.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0191","BK0028","600216","BK0239","BK0188"],"gpt_icon":0},{"id":"2616334339","title":"浙江医药最新公告：子公司新码生物拟实施C轮增资并引入六名战略投资者","url":"https://stock-news.laohu8.com/highlight/detail?id=2616334339","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616334339?lang=zh_cn&edition=full","pubTime":"2026-03-03 17:43","pubTimestamp":1772531014,"startTime":"0","endTime":"0","summary":"浙江医药公告称，公司下属子公司新码生物拟实施C轮增资并引入六名战略投资者，C轮投资人拟合计以人民币6.21亿元的增资款认购新码生物新增注册资本人民币561万元，取得增资后新码生物合计约16.4018%股权。本次增资完成后，浙江医药直接持有新码生物的股权比例由45.9186%变更为37.6347%，新码生物仍为公司的控股子公司，仍纳入公司的合并报表范围。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300031503.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","600216","BK0188","BK0191"],"gpt_icon":0},{"id":"2616843829","title":"每周股票复盘：浙江医药（600216）拟出资2.5亿元参设银发经济基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2616843829","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616843829?lang=zh_cn&edition=full","pubTime":"2026-03-01 01:50","pubTimestamp":1772301020,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，浙江医药报收于16.29元，较上周的16.02元上涨1.69%。本周，浙江医药2月26日盘中最高价报16.71元。浙江医药当前最新总市值156.65亿元，在化学制药板块市值排名34/150，在两市A股市值排名1412/5189。本周关注点公司公告汇总：浙江医药拟出资2.5亿元参与设立银发经济股权投资基金。基金重点投向银发经济及医药大健康领域，存续期限为7年，管理人为中信医疗健康股权投资私募基金管理（北京）有限公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600216","BK0028","BK0191","BK0239"],"gpt_icon":0},{"id":"2613791683","title":"浙江医药（600216）披露与私募基金合作投资公告，2月24日股价下跌1.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613791683","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613791683?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:32","pubTimestamp":1771925558,"startTime":"0","endTime":"0","summary":"近日，浙江医药股份有限公司披露公告，公司与中信医疗健康股权投资私募基金管理（北京）有限公司等合作方共同投资设立廊坊信慧银发经济股权投资基金合伙企业，基金认缴出资总额为8亿元，公司作为有限合伙人以自有资金认缴出资2.5亿元，占比31.25%。基金重点投向银发经济及医药大健康领域，存续期限为7年，管理人为中信医疗健康股权投资私募基金管理（北京）有限公司。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400033121.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0191","600216","BK0028"],"gpt_icon":0},{"id":"2613927798","title":"浙江医药(600216.SH)拟参投合伙企业 投向银发经济/医药大健康领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2613927798","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613927798?lang=zh_cn&edition=full","pubTime":"2026-02-24 15:50","pubTimestamp":1771919448,"startTime":"0","endTime":"0","summary":"合伙企业由中信医疗健康股权投资私募基金管理(北京)有限公司担任普通合伙人、执行事务合伙人和基金管理人。合伙企业重点投向银发经济/医药大健康领域的目标公司，促使被投资企业价值迅速提升，实现基金的设立目标，同时尽合理商业努力获得本基金资本的增值，并努力实现全体合伙人收益的最大化，从而实现多赢的结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406638.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","600216","BK0191","BK1161","BK1515","09939","BK0188","BK0028","BK0239","BK1574"],"gpt_icon":0},{"id":"2609962965","title":"浙江医药：公司已经建立了财务共享体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2609962965","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609962965?lang=zh_cn&edition=full","pubTime":"2026-02-06 21:09","pubTimestamp":1770383340,"startTime":"0","endTime":"0","summary":"证券日报网讯 2月6日，浙江医药在互动平台回答投资者提问时表示，公司已经建立了财务共享体系，该体系正在根据业务实际需要完善调整中，公司根据业务流程特征与合规要求引入不同程度的自动化或智能化工具，公司财务共享体系根据业务需要分布在不同办公区域内。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-06/doc-inhkwwyc1990212.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-06/doc-inhkwwyc1990212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600216","BK0188","BK0028","BK0239","BK0191"],"gpt_icon":0},{"id":"2606358237","title":"每周股票复盘：浙江医药（600216）国投高科减持期满未减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2606358237","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606358237?lang=zh_cn&edition=full","pubTime":"2026-01-25 03:25","pubTimestamp":1769282712,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，浙江医药报收于14.73元，较上周的13.93元上涨5.74%。本周，浙江医药1月23日盘中最高价报14.99元。浙江医药当前最新总市值141.65亿元，在化学制药板块市值排名41/150，在两市A股市值排名1530/5182。公司公告汇总浙江医药股份有限公司持股5%以上股东国投高科技投资有限公司原计划通过集中竞价交易方式减持不超过9,616,377股，减持期间为2025年10月23日至2026年1月22日。本次减持计划未设置最低减持数量，实际减持情况与披露计划一致。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500001207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0028","600216","BK0191"],"gpt_icon":0},{"id":"2605492266","title":"浙江医药（600216）披露持股5%以上股东减持计划届满暨未减持股份公告，1月22日股价上涨1.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605492266","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605492266?lang=zh_cn&edition=full","pubTime":"2026-01-22 22:14","pubTimestamp":1769091259,"startTime":"0","endTime":"0","summary":"近日，浙江医药股份有限公司发布《持股5%以上股东减持计划届满暨未减持股份的公告》。公告显示，公司持股5%以上股东国投高科技投资有限公司原计划通过集中竞价交易方式减持不超过9,616,377股，减持期间为2025年10月23日至2026年1月22日。截至减持计划届满之日，国投高科未实施任何减持，仍持有公司股份150,127,573股，占总股本的15.61%。本次减持计划未设置最低减持数量，实际减持情况与披露计划一致。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200040614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0188","BK0028","600216","BK0239"],"gpt_icon":0},{"id":"2602398555","title":"每周股票复盘：浙江医药（600216）完成1024.4万股限制性股票授予","url":"https://stock-news.laohu8.com/highlight/detail?id=2602398555","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602398555?lang=zh_cn&edition=full","pubTime":"2026-01-11 04:30","pubTimestamp":1768077025,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，浙江医药报收于14.05元，较上周的13.86元上涨1.37%。本周，浙江医药1月7日盘中最高价报14.15元。浙江医药当前最新总市值135.11亿元，在化学制药板块市值排名44/150，在两市A股市值排名1542/5182。本周关注点公司公告汇总：浙江医药完成2025年限制性股票激励计划授予登记，实际授予1,024.4000万股，授予价格7.30元/股，涉及865人。股票来源于二级市场回购，总股本不变。限售期分别为12个月和24个月，分两期各解除限售50%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0188","600216","BK0028","BK0239"],"gpt_icon":0},{"id":"2601526815","title":"浙江医药（600216）披露2025年限制性股票激励计划授予结果，1月6日股价上涨0.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601526815","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601526815?lang=zh_cn&edition=full","pubTime":"2026-01-06 22:45","pubTimestamp":1767710718,"startTime":"0","endTime":"0","summary":"截至2026年1月6日收盘，浙江医药报收于14.06元，较前一交易日上涨0.72%，最新总市值为135.21亿元。公司近日发布公告，披露2025年限制性股票激励计划的授予结果。公告显示，本次限制性股票激励计划的授予日为2025年11月26日，登记日为2026年1月5日，实际授予股份数量为1,024.4000万股，授予价格为7.30元/股，共有865名激励对象获授，包括公司董事、高级管理人员及核心骨干员工。限售期分别为12个月和24个月，解除限售比例分两期各为50%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600042791.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0239","BK0188","BK0028","600216"],"gpt_icon":0},{"id":"2600036136","title":"每周股票复盘：浙江医药（600216）完成限制性股票授予","url":"https://stock-news.laohu8.com/highlight/detail?id=2600036136","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600036136?lang=zh_cn&edition=full","pubTime":"2026-01-02 03:04","pubTimestamp":1767294252,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，浙江医药报收于13.83元，较上周的13.95元下跌0.86%。本周，浙江医药12月22日盘中最高价报14.01元。浙江医药当前最新总市值133.28亿元，在化学制药板块市值排名39/150，在两市A股市值排名1459/5181。本周关注点公司公告汇总：浙江医药向865名激励对象授予1,024.4000万股限制性股票，行权款总额7,478.12万元。本次授予股票来源于公司从二级市场回购的A股普通股，股份性质将由无限售条件流通股变更为有限售条件流通股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600216","BK0188","BK0028","BK0239","BK0191"],"gpt_icon":0},{"id":"2586268215","title":"浙江医药（600216）发布向2025年限制性股票激励计划激励对象授予限制性股票公告，11月26日股价上涨0.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586268215","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586268215?lang=zh_cn&edition=full","pubTime":"2025-11-26 22:22","pubTimestamp":1764166946,"startTime":"0","endTime":"0","summary":"截至2025年11月26日收盘，浙江医药报收于14.03元，较前一交易日上涨0.14%，最新总市值为134.92亿元。该股当日开盘14.0元，最高14.22元，最低13.99元，成交额达1.02亿元，换手率为0.75%。近日，浙江医药发布公告称，公司已于2025年11月26日向875名激励对象授予1,028.4000万股限制性股票，授予价格为7.30元/股。授予条件已满足，限售期分别为12个月和24个月，分两期各解除限售50%。本次股权激励费用将在2025年至2027年摊销，预计总费用为6,921.13万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600038961.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0239","BK0188","BK0028","600216"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774381157356,"stockEarnings":[{"period":"1week","weight":-0.0608},{"period":"1month","weight":-0.0649},{"period":"3month","weight":0.0816},{"period":"6month","weight":0.0439},{"period":"1year","weight":0.1332},{"period":"ytd","weight":0.0808}],"compareEarnings":[{"period":"1week","weight":-0.0416},{"period":"1month","weight":-0.0492},{"period":"3month","weight":-0.0151},{"period":"6month","weight":0.0073},{"period":"1year","weight":0.1517},{"period":"ytd","weight":-0.0221}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"63021人(较上一季度减少3.83%)","perCapita":"15096股","listingDate":"1999-10-21","address":"浙江省绍兴市越城区滨海新城致远中大道168号","registeredCapital":"96163万元","survey":" 浙江医药股份有限公司的主营业务是生命营养品、药品。公司的主要产品是合成维生素E、维生素A、天然维生素E、维生素H(生物素)、维生素D3、辅酶Q10、β-胡萝卜素、斑蝥黄素、叶黄素、番茄红素等维生素和类维生素产品、医药制造类产品及医药商业。报告期内，公司在CPHI2025荣获“LeadingEnterpriseofPharmaInternationalizationAwards”（医药国际化领军企业奖），在HHB健康美丽产业高质量发展大会被评为“健康美丽产业绿色可持续发展先锋企业”。","listedPrice":5.16},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"浙江医药(600216)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供浙江医药(600216)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"浙江医药,600216,浙江医药股票,浙江医药股票老虎,浙江医药股票老虎国际,浙江医药行情,浙江医药股票行情,浙江医药股价,浙江医药股市,浙江医药股票价格,浙江医药股票交易,浙江医药股票购买,浙江医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"浙江医药(600216)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供浙江医药(600216)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}